Diastase Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Multiple Phase 3 clinical trials sponsored by Takeda and Takeda Development Center Americas Inc. are currently evaluating therapeutic interventions exclusively for Alpha1-Antitrypsin Deficiency. With recruitment statuses ranging from active recruiting to enrolling by invitation, these late-stage investigations aim to assess the safety, therapeutic efficacy, and long-term outcomes of targeted regimens in affected patients.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06165341	Recruiting	Alpha1-Antitrypsin Deficiency	Takeda	2024-03-01	Phase 3
NCT05899673	Enrolling by invitation	Alpha1-Antitrypsin Deficiency	Takeda	2023-08-08	Phase 3
NCT05677971	Recruiting	Alpha1-Antitrypsin Deficiency	Takeda\|Takeda Development Center Americas Inc.	2023-03-06	Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Diastase product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an amylolytic enzyme, diastase binds specifically to starch polymers and catalyzes the hydrolytic degradation of glycosidic linkages into maltose disaccharides. This biochemical breakdown reduces complex carbohydrate accumulation and supports metabolic homeostasis, providing clinical relevance for metabolic management in conditions such as Alpha1-Antitrypsin Deficiency.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).